The budget impact of alteplase in the treatment of acute ischemic stroke in Egypt.

Autor:	Aref H; Department of Neurology, Faculty of Medicine, Ain Shams University, Cairo, Egypt., El Nahas N; Department of Neurology, Faculty of Medicine, Ain Shams University, Cairo, Egypt., Elsisi GH; HTA Office, LLC, Cairo, Egypt.; Department of Economics, American University in Cairo, Cairo, Egypt., Shokri H; Department of Neurology, Faculty of Medicine, Ain Shams University, Cairo, Egypt., Roushdy T; Department of Neurology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Jazyk:	angličtina
Zdroj:	Frontiers in neurology [Front Neurol] 2023 Nov 08; Vol. 14, pp. 1220615. Date of Electronic Publication: 2023 Nov 08 (Print Publication: 2023).
DOI:	10.3389/fneur.2023.1220615
Abstrakt:	Introduction: Stroke is the second leading cause of mortality worldwide. Five percent of all the disability-adjusted life years (DALYs) lost around the world are attributed to stroke. This study aimed to assess the economic burden of acute ischemic stroke (AIS) in Egypt and reveal the benefits of alteplase treatment by measuring the resource use and costs associated with this treatment compared to the standard of care and extrapolate the overall budget impact of alteplase to the local Egyptian setting over a 5-year time horizon from a societal perspective. Methods: A budget impact model was developed to estimate the impact of adding alteplase to the current treatment of AIS patients within the Egyptian healthcare setting. The efficacy data for both arms of the model were sourced from a systematic review of the literature. Resource use and cost data were sourced from a retrospective study. Proportions of patients potentially eligible for treatment and the treatment time distributions were estimated from an analysis of the results of this retrospective data collection. A univariate sensitivity analysis was conducted to assess the robustness of the model results. The input parameters varied between plausible extremes based on a review of available evidence. Results: The total annual costs with alteplase treatment [i.e., drug, symptomatic intracerebral hemorrhage (ICH) management, acute hospitalization, and post-hospitalization costs] for the targeted patients from a societal perspective were estimated to be less than the total annual costs without alteplase. This resulted in savings of approximately EGP 37.2 million ($ 1.2 million), EGP 14.2 million ($ 458.06), EGP -33.0 million ($ -1.06 million), EGP -54.0 million ($ -1.74 million), and EGP -89.8 million ($ -2.89 million) for each of the 5 years, respectively. In year 1, more than 2,787 patients (+30.1%) achieved an excellent outcome and <1,204 patients (-22.3%) had a poor outcome when treated with alteplase. The savings in acute hospitalization and post-hospitalization costs offset the increase in drug and ICH management costs in the alteplase group compared to treatment without alteplase. The total cumulative cost savings for alteplase in AIS patients were estimated at EGP -228,146,871 ($ -7,359,576) over 5 years. Conclusion: The budget impact model estimates suggest that from a societal perspective, alteplase is likely to be a cost-saving option for the treatment of AIS in Egypt due to the treatment benefits, resulting in savings in acute hospitalization and annual post-hospitalization costs. Competing Interests: GE was employed by HTA Office, LLC. The authors declare that this study received funding from Boehringer Ingelheim covering the payment for statistical analysis and the open access publication fees. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication. (Copyright © 2023 Aref, El Nahas, Elsisi, Shokri and Roushdy.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu